Posttraumatic stress disorder (PTSD) is a debilitating mental health condition that increases suicide risk and affects up to 20% of military veterans and 8% of the general population. Prolonged Exposure (PE) is a highly efficacious, evidence-based, cognitive-behavioral therapy for PTSD. However, dropout rates are high (25-30%) and an estimated one-third of patients who complete PE remain symptomatic. This study directly addresses these limitations by obtaining patient perspectives on an innovative technology system that will help to personalize optimization of a critical component of PE: In Vivo Exposure (IVE).
The study will collect information from patients who have received treatment for posttraumatic stress disorder (PTSD) about their thoughts, preferences, and suggestions for ways to incorporate mobile technologies into PTSD treatment.
As a result of sustained operations in Afghanistan and Iraq, there are an increasing number of U.S. military Veterans with substance use disorders and comorbid posttraumatic stress disorder (PTSD). If left untreated, individuals with substance use disorders and PTSD are at increased risk for developing other mental health problems (e.g., depression, anxiety), suicidal ideation and attempts, medical problems, reduced resiliency and military readiness, vocational problems, and family/social impairment.Determine the benefits of N-acetylcysteine (NAC) in treating alcohol use disorder and comorbid post-traumatic stress disorder (PTSD) among military Veterans.
The purpose of this study is to evaluate the effects of a medication (doxazosin) on reducing symptoms of posttraumatic stress disorder (PTSD) and substance use in Veterans. We will also examine the effects of doxazosin on brain activity at pre and post treatment.